The use of oral therapies for chronic lymphocytic leukemia has had a great impact on patient outcomes and quality of life. Pharmacists can play a key role in assisting with therapy selection, education for patients and the healthcare team, and also managing adverse effects for patients receiving these therapies.

Objectives

Differentiate novel therapies for the treatment of chronic lymphocytic leukemia (CLL) by pharmacologic properties and special considerations for use

Associate drug therapy and safety and efficacy information with treatment selection for patients with CLL

Dr. Katherine Tobon is a clinical pharmacy specialist in malignant hematology with Moffitt Cancer Center in Tampa, Florida.

Dr. Tobon has no relevant financial relationships with commercial interests to disclose.

Accreditation and support statement: 

PTCE is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours of knowledge-based credit.

This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., Administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd.

Learn more about your ad choices. Visit megaphone.fm/adchoices